Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and BeyondSpring (NASDAQ:BYSI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of recent ratings for Oramed Pharmaceuticals and BeyondSpring, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Oramed Pharmaceuticals and BeyondSpring’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -7.57% | -6.58% |
| BeyondSpring | N/A | N/A | -42.62% |
Risk and Volatility
Oramed Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
Valuation & Earnings
This table compares Oramed Pharmaceuticals and BeyondSpring”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 81.54 | $64.05 million | $6.16 | 0.64 |
| BeyondSpring | $1.75 million | 13.84 | -$1.01 million | ($0.12) | -4.91 |
Oramed Pharmaceuticals has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Oramed Pharmaceuticals beats BeyondSpring on 9 of the 12 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.
About BeyondSpring
BeyondSpring is a biopharmaceutical company focused on developing therapies for cancer and complications associated with cancer treatment. Its research and development activities center on oncology drug candidates and supportive-care treatments. The company’s lead candidate is plinabulin, a small-molecule drug being investigated for use in preventing chemotherapy-induced neutropenia, a potentially serious drop in infection-fighting white blood cells. BeyondSpring has also studied plinabulin for its potential anti-cancer effects, including in lung cancer.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
